• Healthcare providers are increasingly prioritizing specific, high-impact AI applications that enhance patient care and financial performance.
• Adageis’ ProActive Care Platform leverages AI to enhance risk assessment, workflow optimization, and revenue tracking for providers.
• AI-driven patient monitoring and early intervention reduce hospital readmissions and improve care quality.
• Adageis’ Patented Risk Engine helps healthcare providers proactively address high-risk patients, improving outcomes while increasing reimbursements.
• Seamless integration with multiple EHR systems ensures easy adoption without disrupting provider workflows.

As in other areas, artificial intelligence is making a measurable impact on healthcare, but the focus is shifting. While artificial general intelligence (“AGI”) once dominated AI discussions, healthcare providers are now increasingly prioritizing specific, high-impact AI use cases and applications that enhance patient care and financial performance. This transition is being driven by value-based care models, which require providers to demonstrate improved patient outcomes rather than simply increasing service volume.

Companies like Adageis, a leading healthcare technology company, are at the forefront of this shift, delivering AI-driven tools that optimize patient care, track revenue, and improve operational efficiency. Adageis develops AI-centric solutions tailored to providers, Accountable Care Organizations (“ACOs”), and Clinically Integrated Networks (“CINs”). Its ProActive Care Platform is designed to integrate seamlessly into existing workflows, offering practical applications that directly impact revenue generation and patient care.

Key areas where Adageis’ AI solutions are making a difference:

• Risk Identification & Early Intervention: The Patented Risk Engine analyzes patient data to identify individuals at risk for chronic diseases or complications. By flagging high-risk patients early, providers can proactively intervene, reducing hospital readmissions and lowering costs.
• Revenue Tracking & Forecasting: Adageis simplifies value-based care revenue management by providing real-time insights into provider performance. AI-driven analytics ensure accurate revenue tracking across multiple providers, making it easier to align with payer incentives.
• Clinical Decision Support: The platform integrates with nearly 100 electronic health record (“EHR”) systems like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, offering real-time insights at the point of care. This ensures that clinicians receive actionable recommendations without disrupting workflows.
• Administrative Task Automation: Beyond clinical applications, Adageis helps providers manage supply chains, resource allocation, and documentation, increasing efficiency and reducing administrative burdens.
• Continuous Patient Monitoring: AI-powered efficiency monitoring tools allow real-time tracking of patient health trends, ensuring timely interventions between visits. This leads to fewer emergency department visits and better overall patient outcomes.

The healthcare industry’s transition to value-based care is well underway, but many providers struggle with the financial complexities of this model. AI tools like those developed by Adageis help organizations meet value-based care metrics, ensuring they maximize reimbursements while improving patient care.

Adageis’ Value-Based Care Engine provides automated performance tracking to ensure compliance with payer requirements, optimized patient care strategies that improve reimbursement rates, as well as advanced analytics that help providers predict and manage costs. By streamlining complex processes, Adageis makes it easier for healthcare organizations to generate revenue while improving patient outcomes.

As AI continues to evolve, the shift from AGI to highly targeted applications in healthcare will accelerate. Companies like Adageis are demonstrating how AI can deliver tangible results, helping providers navigate the challenges of value-based care with precision and efficiency, improving financial performance, and enhancing patient outcomes—all without adding complexity to providers’ workflows.

“We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with,” Adageis CEO Shane Speirs said recently. “Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Electronic monitoring (“EM”) technology developer SuperCom has developed a full range of best-in-class technology products and accompanying services to help criminal justice agencies reduce recidivism and incarceration costs while increasing rehabilitation potential for offenders
• The company recently reported a new contract win, its seventh domestic violence EM project on a national level
• In addition to national contract expansion throughout Europe, SuperCom has reported 20 new EM contracts throughout the United States
• Market analysts have noted the growing call for EM products and services, with marked increased usage in North America, Latin America, and Europe in recent years, underscoring SuperCom’s continued growth

SuperCom (NASDAQ: SPCB), a company specializing in electronic monitoring (“EM”) technology to help public safety agencies reduce the incidence of repeated domestic violence (“DV”), is announcing a new EM contract win that expands its portfolio of national DV monitoring projects.

The use of EM technology as an alternative to incarceration has been increasing on a global scale since public safety agencies in the United States began working with it in the 1980s. Last year, market analysts at ResearchAndMarkets.com and Berg Insight both reported that the number of participants in EM programs reached about 518,000 in North America, 130,000 in Latin America, and 64,000 in Europe during 2023 (https://ibn.fm/dZEL2).

The analysts forecast the number of participants in these EM programs will increase to about 680,000 in North America, 239,000 in Latin America, and 94,000 in Europe by 2028, underscoring the rising pace of new participants as government officials seek the means for cutting prison system costs while continuing to ensure the safety of their communities.

Overall, Berg reported that by the end of 2023, nearly 1.4 million people had participated in an EM supervision program, with nearly two-thirds of them in the United States (https://ibn.fm/BR3VF). SuperCom’s latest contract brings its current list of national EM of DV projects to seven, including announced services for the state police of Latvia (https://ibn.fm/eDQds) and Romania’s Ministry of Interior (https://ibn.fm/S7O7k).

The company noted it is outpacing its competitors with its expansion and is demonstrating its reputation as a leader in providing DV monitoring solutions. In addition to its large ongoing European expansion, SuperCom has signed 20 new contracts for technological solutions throughout the United States since last August, including services in six states where SuperCom’s products are being used for the first time (https://ibn.fm/VpDhJ).

The company also notes the technology’s potential for reducing recidivism (repeated offenses) by helping suspects and convicted offenders who qualify for EM monitoring to return to everyday work, school, and home activities while wearing a tech device that is discreet and easily recharged.

“We are pleased to see another national government choose our DV advanced electronic monitoring solutions, demonstrating the strong trust governments place in our technology and their satisfaction with its effectiveness,” SuperCom President and CEO Ordan Trabelsi stated in the company’s most recent announcement. “SuperCom continues to strengthen its position as a trusted partner for government agencies seeking effective, scalable solutions for public safety. With each new deployment, we help authorities enhance victim protection and offender compliance, driving real impact in communities.”

SuperCom uses both radio frequency (“RF”) and GPS, the dominant technologies in the EM market, to provide at-home and on-the-street supervision of offenders by the criminal justice system, which is suited to clients’ needs.

The company’s advanced PureTrack GPS platform includes branded technology elements such as the wearable bracelets PureOne (GPS) and the PureTag (RFID), the home base station PureCom, and the PureProtect mobile app.

SuperCom has a track record of more than 50 government clients served, monitoring more than 100,000 individuals.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• SolarBank and Viridi are collaborating on a 3.06 MW solar and 1.2 MWh battery energy storage system in Buffalo, New York, repurposing a closed landfill, converting unused land into a source of clean energy.
• Pending approvals and financing, SolarBank is set to begin construction, while Viridi will provide the battery storage system.
• Viridi’s battery systems include integrated fire suppression and anti-propagation technology to enhance safety.
• Once operational, the project will function under a community solar model, where residents can subscribe to the project, earning credits on their electricity bills without installing personal solar panels.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced a partnership with Viridi, the industry leader in fail-safe battery energy storage systems (“BESS”), to develop a combined 3.06 megawatt (“MW”) direct current ground-mounted solar power project and a 1.2 megawatt-hour (“MWh”) BESS, in Buffalo, New York. This initiative aims to transform a closed landfill into a productive asset that generates clean energy for the local community (https://ibn.fm/XEmgk).

The selected site, located at 1037 South Park Ave. in South Buffalo, was previously a landfill. By repurposing this land, the project not only addresses environmental concerns but also contributes to the community by providing a sustainable energy source. This approach exemplifies innovative land use, turning otherwise unusable areas into hubs for renewable energy production.

Once operational, the project will function under a community solar model. This setup allows local residents, including renters and homeowners, to subscribe to the solar project. Subscribers receive credits on their electricity bills corresponding to their share of the generated solar energy, enabling them to benefit from renewable energy without the need to install personal solar panels. This model promotes inclusivity and broad participation in clean energy initiatives.

Viridi, known for its leadership in fail-safe battery energy storage systems, will supply the BESS for this project. Their innovative lithium-ion battery packs are equipped with integrated fire suppression and pioneering anti-propagation technology. Unlike traditional methods that modify battery cells, Viridi’s design isolates each cell to prevent thermal runaway, ensuring that a single cell failure does not escalate. This fail-safe approach enhances safety and reliability, making the energy storage solution adaptable for various settings.

SolarBank, subject to the receipt of financing, intends to be the owner of the project. The company has secured a lease for the project site and has applied for interconnection approval. Upon receiving the necessary permits and financing, the company plans to commence construction. The integration of the BESS with the solar installation will allow for the storage of generated energy, which can be dispatched during peak demand periods, thereby enhancing grid stability and optimizing energy use. This project aligns with New York State’s energy storage roadmap, which supports the development of such hybrid generation-storage projects.

SolarBank has already begun construction on another BESS project, representing the company’s first foray into this sector. The company has kicked off construction of project SFF-06, one out of two battery energy storage systems in Ontario, earlier in February 2025, through a $25.8 million CAD ($18.17 million USD) project finance facility from the Royal Bank of Canada. The initiatives come as battery storage demand surges, with the global market projected to reach $31.2 billion USD by 2029, growing at 16.3% annually (https://ibn.fm/G6g5b).

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, remains on track to acquire a 52% stake in Italian Serie B soccer club SS Juve Stabia
• Its investments are paying off, with Andrea Adorante, a star forward on the team, now having an estimated purchase value of close to €6-7 million, projected to climb to €8-10 million should he continue at his current goal-scoring pace
• Adorante has scored 12 goals with 2 assists so far in the current football season and could end up with 18 at that pace, winning fans and media, plus Player of the Week on the 26^th week of the season
• Adorante’s valuation could surpass Brera’s €7.5 million investment for its SS Juve Stabia acquisition, as well as the Nasdaq company’s current estimated overall valuation, all pointing to a massive overlooked opportunity for any investor

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, remains on track to acquire a 52% stake in Italian Serie B club, SS Juve Stabia “The Second Team of Naples.” Andrea Adorante, a star forward at the team, already has an estimated purchase value of between €6 to €7 million, projected to climb to €8-10 million should he continue at his current pace, according to Italian media reports. 

Brera Holdings, with a portfolio comprising six teams globally covering primarily both men’s and women’s football clubs, currently holds a 38.46% ownership equity in Juve Stabia, with the third and last of the multi-step acquisition set to close on March 31, 2025, making Brera the majority shareholder in the club (https://ibn.fm/XchS6).

Amazingly, this means that a single player for the Brera club Juve Stabia has an estimated asset sales value as high as that of the current full purchase price Brera is paying for its majority ownership of The Second Team of Naples, making it a significant overlooked opportunity for investors.

Earlier in February, it was estimated in an independent CFA research report that Juve Stabia’s 2025 revenue would increase by $5.15 million, with Brera’s overall revenue forecast estimated at between $6.3 million and $9.8 million. The projections have implied a market capitalization of $55.76 million by 2027, further projecting its MCO model’s viability (https://ibn.fm/W7S1D).

“Brera Holdings has made a strategic move with the Juve Stabia acquisition, and while challenges remain, the company is positioning itself for significant revenue growth,” noted Sascha P. Czerwenka, CFA, for 247MarketNews.com. “If operational improvements continue as expected, the stock could see a major re-rating, presenting a compelling opportunity for investors,” he added (https://ibn.fm/W7S1D).

So far in the current football season, Adorante has scored 12 goals and is projected to end up with 18 for the season. This impressive feat marks a striking year since he joined Juve Stabia on January 4, 2024. The 25-year-old Italian has made 25 match appearances for Juve Stabia, getting two assists in addition to his 12 goals (https://ibn.fm/OSsHd). He has also won accolades, including Player of the Week on the 26^th week of the current season, and has become a media and fan star. 

Having a single player with a higher estimated purchase value than that of the overall club, let alone the Nasdaq-listed company Brera that owns it, makes no sense, and should represent a hidden buying opportunity to any investor.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts.
• Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline.
• The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented technology that protects and potentiates the virotherapy during administration (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) to target and destroy cancer cells while simultaneously stimulating the immune system. The company’s groundbreaking work has positioned it as a leader in the development of next-generation cancer treatments.

In recent news, Calidi has made two major announcements that underscore its progress, one related to its strengthened financial position and another highlighting its acceptance into a prestigious scientific seminar to present new research. These developments signal the company’s growth and its continued advancement toward commercializing its therapies.

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi Biotherapeutics recently announced that it has strengthened its financial position, ensuring continued progress in its clinical and preclinical programs (https://ibn.fm/9JicX). As of Dec. 31, 2024, Calidi reported a cash balance of approximately $9.6 million. This increase is largely due to successful fundraising efforts, including proceeds from the company’s At-the-Market Offering Agreement (“ATM”).

As a result of these efforts, Calidi was able to terminate its Standby Equity Purchase Agreement (“SEPA”) with YA II PN Ltd., an affiliate of Yorkville Advisors, effective Jan. 23, 2025. The infusion of capital will allow the company to further refine its oncolytic virotherapy platforms, expand its clinical trials, and enhance its overall operational stability.

Additionally, Calidi announced the successful closing of a public offering on Jan. 10, 2025, which raised an additional $4.25 million in gross proceeds. This contributes to the ongoing development of Calidi’s proprietary technologies and supports the company’s mission to bring effective cancer therapies to market. This improved financial footing not only reassures investors but also allows Calidi to focus on achieving key milestones in its research pipeline. With adequate funding in place, the company is well-positioned to continue its groundbreaking work in cancer immunotherapy.

Beyond its financial achievements, Calidi Biotherapeutics has also made headlines for its acceptance into a major scientific conference where it will present its latest research findings (https://ibn.fm/WZ1RO). The company announced that it has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious American Association for Cancer Research (“AACR”) annual meeting in April 2025.

This recognition marks an important milestone for Calidi, as the AACR annual meeting is one of the most influential conferences in the field of cancer research. Being accepted to present at this event underscores the significance of Calidi’s work and its potential to revolutionize cancer treatment.

Calidi’s RTNova platform is designed to overcome the limitations of traditional virotherapy by enabling systemic delivery and enhancing the targeting of metastatic tumors. Antitumor virotherapies have long been recognized for their ability to selectively infect and kill cancer cells, but challenges such as immune system clearance and limited distribution have hindered their full potential. The RTNova platform addresses these challenges by utilizing an extracellular enveloped virus (“EEV”) as a delivery mechanism, allowing the therapeutic viruses to reach tumors more effectively while evading premature destruction by the immune system. These preclinical findings highlight the RTNova platform’s ability to effectively target and treat metastatic cancer cells and represent a significant advancement in the field of cancer virotherapy.

In addition to the RTNova platform, Calidi is actively developing other innovative therapies aimed at harnessing the immune system to combat cancer. The company’s approach to immunotherapy focuses on protecting the viral payload to enhance the efficacy of antitumor viruses, potentially improving outcomes for patients with hard-to-treat cancers.

With a strengthened financial position and the recognition of its research by a leading scientific organization, Calidi Biotherapeutics is poised for continued growth. The company’s ability to secure funding ensures that it can maintain momentum in its clinical and preclinical programs, while its acceptance into a high-profile scientific seminar validates the importance of its work. As Calidi moves forward, it is well-positioned to make a lasting impact in the biotechnology industry. With continued innovation and a strong financial foundation, the company is set to play a crucial role in the future of cancer immunotherapy.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• Adageis streamlines complex insurance contracts, helping providers maximize reimbursements.
• The company’s AI-driven solutions reduce administrative burden, freeing up time for patient care.
• Seamless integration with nearly 100 EHR systems ensures a smooth transition to value-based care models.
• The company’s fintech approach enhances financial performance, with providers seeing up to $75,000 in additional revenue.
• Adageis projects significant growth, expecting to cover 580,000 patient lives by mid-2025.

Healthcare is shifting toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures that can be difficult to navigate.

Adageis, a healthcare technology company providing smart AI-centric software solutions for healthcare organizations, is helping providers optimize care delivery while maximizing revenue. The company’s AI-driven platform integrates with nearly 100 electronic health record (“EHR”) systems, making it easy for medical practices to track performance metrics and meet insurers’ evolving documentation requirements.

“One of the major challenges in the marketplace is the sheer complexity — there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance,” Adageis CEO Shane Speirs said during a recent podcast (https://ibn.fm/7yFnW).

According to Speirs, what Adageis focuses on is to provide a simple solution to healthcare organizations — ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. “We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with,” the Adageis CEO said. “Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

Another issue the healthcare system is facing is the fact that administrative tasks, such as clinical documentation and coding, consume valuable time that could be spent on patient care. Adageis addresses this issue with its AI Scribe technology, which uses ambient listening to automate documentation and coding. By leveraging AI, the platform:

• Reduces administrative workload, allowing providers to focus on patient care.
• Generates high-quality coding, ensuring maximum reimbursement.
• Minimizes errors in documentation, lowering the risk of rejected claims.

This approach enhances financial performance, with some providers seeing up to $75,000 in additional annual revenue from value-based care incentives, according to figures listed in the company’s investor deck.

Adageis is positioning itself as a leader in healthcare fintech, as the only healthcare fintech company in the marketplace, bridging the gap between financial optimization and improved patient care. The company’s growth projections underscore its increasing market presence:

• Currently covering 150,000 patient lives, with plans to reach 580,000 by mid-2025.
• $100,000 in monthly recurring revenue expected by Q2 2025.
• Expanding provider base, onboarding 2-3 new clients per month.

By integrating financial technology with AI-driven healthcare solutions, Adageis is reshaping how providers approach value-based care, ensuring better patient outcomes while driving revenue growth. Allowing providers to simplify complex financial structures while maintaining quality care, Adageis offers a scalable, easy-to-implement platform, reducing inefficiencies and ensuring forward-thinking providers thrive in a rapidly evolving landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

Traders, dealers, businesses, and enthusiasts of the cannabis industry are invited to attend the New England Cannabis Convention in Boston from March 21 to March 22, 2025. Operating since 2015, NECANN events are referred to as “MJBizCon East.” The second largest B2B event in the U.S., NECANN witnesses thousands of attendees, with the largest gathering of licensed operators, exhibitors, buyers, and leaders, for the East Coast cannabis market. These events are considered the home base for the Northeast cannabis industry.

The Boston NECANN Convention 2025 will also host the prize-giving ceremony for the Boston NECANN Cup winners on March 22, 2025. Registrations for this close on February 23, 2025. Applications are also invited to judge the NECANN Boston Cup. The NECANN Cup is New England’s only multi-state cannabis competition, a third-party blind evaluation of cannabis and cannabis products (https://ibn.fm/duCNZ).

NECANN events are considered a major benefit to the Northeast cannabis industry, offering a phenomenal platform for networking and business to the local cultivators, traders, pharmacies, and more. Each year, the event witnesses 9,000+ attendees, interacting, networking, and attending the 60+ programming sessions. Over 300+ exhibitors, with 100+ licensed cultivators, retailers, and brands, exhibit their latest products and technologies on the exhibition floor.

Investors can discover new avenues of investment while entrepreneurs can gain visibility among the leading businesses and experts in the cannabis industry. Cannabis industry stalwarts will conduct the different programming sessions at NECANN Boston. They will address the most compelling cannabis industry topics faced by operators in Massachusetts. Some important topics that will be covered include regulatory compliance services, consumer market study, and advocacy of psychedelic-assisted therapies in conservative states, to name a few.

To learn more, please visit https://ibn.fm/KSQ7t.

• According to the American Cancer Society, cancer is the second leading cause of death globally.
• Oncology drugs are a cornerstone of modern cancer treatment.
• Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments.

Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.

According to the American Cancer Society, cancer is the second leading cause of death globally, with 2,001,140 new cancer cases and 611,720 cancer deaths projected to occur in the United States in 2024 (https://ibn.fm/JA0DN). Approximately one in six deaths worldwide is due to cancer. The global cancer burden is expected to rise to 28.4 million cases by 2040, a 47% increase from 2020. This surge is driven by population growth, aging, and lifestyle factors such as tobacco use, poor diet, and physical inactivity.

Among the most prevalent and deadly forms of cancer are lung cancer, which is responsible for 1.8 million deaths annually, making it the leading cause of cancer-related mortality (https://ibn.fm/woQzB); colorectal cancer, which accounts for nearly 935,000 deaths each year (https://ibn.fm/ms7ty); breast cancer, the most commonly diagnosed cancer, with more than 2.3 million new cases annually (https://ibn.fm/O313h); and stomach and liver cancers, which account for approximately 968,784 (https://ibn.fm/zyWfM) and 866,136 deaths per year, respectively (https://ibn.fm/4EvTp).

These statistics highlight the enormous need for effective cancer treatments, especially for high-mortality cancers such as glioblastoma (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and certain types of lung cancer.

Oncology drugs are a cornerstone of modern cancer treatment. These drugs range from traditional chemotherapy to targeted therapies and immunotherapies, which aim to enhance the body’s immune response against cancer cells. Oncology drugs play a vital role in:

• Extending Survival: Many advanced therapies have significantly improved survival rates for cancers once considered untreatable.
• Improving Quality of Life: Targeted treatments and immunotherapies often come with fewer side effects than traditional chemotherapy, allowing patients to maintain a better quality of life.
• Personalized Medicine: Advances in genetic testing have enabled the development of personalized oncology drugs tailored to the unique genetic makeup of a patient’s tumor.

The global oncology drug market was valued at approximately $158 billion in 2022 and is projected to reach $327 billion by 2037, reflecting a compound annual growth rate (“CAGR”) of 7.5% (https://ibn.fm/xBVyH). However, despite these advances, significant gaps remain in treatment efficacy, accessibility, and affordability, underscoring the urgent need for continued innovation.

Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Their unique approach leverages antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. Calidi’s therapeutic strategy centers on harnessing the power of antitumor virotherapies, which are engineered to selectively infect and destroy cancer cells while sparing healthy tissue.

To enhance the delivery and efficacy of these viruses, Calidi uses extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms to protect the virotherapy from the body’s immune system during administration. The company’s dual approach offers multiple advantages, including targeted tumor destruction, in which viruses directly attack cancer cells, leading to their destruction; and immune system activation, a process that triggers a systemic immune response and trains the immune system to recognize and attack cancer cells throughout the body.

Calidi’s robust pipeline includes three key product candidates:

• RTNova (“CLD-400”): Targeting lung cancer and metastatic cancer, RTNova is a systemic platform that can be administered intravenously. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.
• SuperNova (“CLD-201”): Targeting solid tumors such as head and neck, triple-negative breast cancer and soft tissue sarcoma, SuperNova combines mesenchymal stem cells with vaccinia viruses. This therapy aims to overcome the limitations of traditional treatments by directly targeting tumors and activating the immune system.
• NeuroNova (“CLD-101”): This therapy is designed for patients with glioblastoma and other high-grade gliomas. It utilizes neural stem cells to deliver antitumor viruses directly to brain tumors, offering a promising new approach for one of the most aggressive and treatment-resistant cancers.

Calidi is also developing next-generation engineered antitumor viruses to broaden the scope of cancers treatable with its platform.

The groundbreaking work being done by Calidi Biotherapeutics has the potential to transform the oncology drug market and significantly improve cancer care. By focusing on high-need cancer types such as GBM, TNBC, sarcoma and lung cancer, Calidi addresses critical gaps in current treatment options. The company’s innovative therapies not only aim to improve survival rates but also reduce the debilitating side effects associated with many existing cancer treatments. As Calidi’s products advance through clinical trials, they hold the promise of offering new hope to patients facing some of the most challenging cancers.

The global burden of cancer continues to grow, making the need for effective oncology drugs more pressing than ever. As a leader in innovative cancer treatment, Calidi Biotherapeutics is poised to play a pivotal role in shaping the future of oncology drug development. Its pioneering therapies represent a new frontier in the fight against cancer, offering hope for improved outcomes and a better quality of life for millions of patients worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• The company’s six-month revenue reached $20.1 million CAD ($14.15 million USD), reflecting steady long-term growth despite seasonal fluctuations.
• Gross profit margin increased to 29.2%, up from 18.4% in the prior year, signaling improved margins.
• Assets surged 372% to $185.3 million CAD ($130.47 million USD) during the six month period, following the acquisition of Solar Flow-Through Funds Ltd.
• Recent $70.3 million CAD ($49.5 million USD) deal with Qcells will drive revenue in upcoming quarters.
• Share price more than doubled in early February, signaling investor interest.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., posted its fiscal 2025 second-quarter results, emphasizing its six-month revenue of $20.1 million CAD ($14.15 million USD) and improved gross margins. According to the Q2 results, the company’s gross profit rose to $5.9 million CAD ($4.15 million USD) (or 29.2% of revenues), from $4.8 million CAD ($3.38 million USD) in 2024, reflecting a shift toward higher-margin business lines (https://ibn.fm/F30Jw).

Additionally, independent power producer (“IPP”) revenue increased from CAD $0.14 million ($0.07 million USD) to $5.4 million CAD ($3.8 million USD) during the same six-month period, with assets growing 372% to $185.3 million CAD ($130.47 million USD) following the acquisition of Solar Flow-Through Funds Ltd., as compared to $39.2 million CAD ($27.6 million USD) on June 30, 2024. The company ended the second quarter of fiscal 2025 with $33.6 million CAD ($23.66 million USD) in current assets, as compared to $17.6 million CAD ($12.39 million USD) in current assets as of year-end June 30, 2024. The increase is principally the result of the closing of the Solar Flow-Through Funds acquisition.

In addition to the encouraging Q2 results, the company’s stock saw a sharp rally in early February, rising from $3.86 CAD ($2.72 USD) on Jan. 31 to $9.08 CAD ($6.39 USD) by Feb. 10. While the price has since stabilized, the spike suggests growing investor interest in the company’s strategic direction and upcoming projects (https://ibn.fm/ZiPvC).

Beyond the current financials report, SolarBank is positioning itself for sustained expansion moving forward, recently securing additional major financing and strategic partnerships:

• $70.3 million CAD ($49.5 million USD) transaction with Qcells to sell and construct four solar projects in New York, with revenues to be recognized in future quarters (https://ibn.fm/QOyJY). The projects will utilize high-quality Qcells modules that will be manufactured in the U.S. The deal is part of the nearly $2.8 billion USD being invested by Qcells to boost U.S. domestic solar manufacturing and innovation to support and accelerate the U.S. clean energy transition.
• $25.8 million CAD ($18.17 million USD) project finance facility from RBC to develop two battery energy storage systems (“BESS”) in Ontario, a sector with strong long-term growth potential. Representing the company’s first foray into the battery storage sector, construction on the first project, SFF-06, began during the Feb. 10 week (https://ibn.fm/5WEhQ).
• 145 MW of solar projects in the pipeline, expected to reach notice to proceed within the next 12 months.

These projects reinforce SolarBank’s focus on securing stable, recurring revenue streams, including independent power production.

CEO Richard Lu acknowledged that seasonal factors affected Q2 revenue, a common trend in the solar industry, especially in winter months. However, higher-margin power production and asset growth offset the slight decline, leading to improved overall gross profits. “This is stable recurring revenue that is under long-term contracts, and we will continue to grow this business as evidenced by the $25.8 million Royal Bank of Canada debt facility that supports the construction of the BESS projects that we own,” Lu said.

The CEO also pointed out that delays in EPC (engineering, procurement, and construction) revenue were expected, as the company focused on securing a strong development partner. The Qcells deal, finalized at the end of the quarter, means these revenues will now be reflected in the coming periods, he added.

SolarBank’s strong asset growth, rising profit margins, and new revenue streams from power production and storage projects position the company well for continued success. With a robust project pipeline and investor interest reflected in the recent stock price rally, SolarBank sees itself well-positioned for sustained growth in the renewable energy market.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://finance.yahoo.com/news/solarbank-announces-second-quarter-results-120000457.html and the press release referenced in this article for additional details on the nature, assumptions and risk factors associated with this forward looking information.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Manufacturing within the U.S. offers numerous benefits that can significantly impact a company’s operational efficiency and market competitiveness
• The Massimo Group’s recent announcement highlights the company’s proactive approach in leveraging these benefits
• “We are committed to providing our customers with the highest quality golf carts while ensuring long-term business sustainability,” states the CEO

In recent years, manufacturing goods in the United States has become increasingly advantageous for companies aiming to enhance quality control, reduce lead times and navigate complex international trade dynamics. Recent tariff announcements have made the move to U.S. soil even more compelling. Massimo Group (NASDAQ: MAMO), a prominent player in the powersports industry, has exemplified this trend by announcing the relocation of its MVR Golf Cart series production to its Garland, Texas, facility (https://ibn.fm/34Aav). This strategic move not only underscores the benefits of domestic manufacturing but also aligns with the company’s vision of delivering superior products while adapting to evolving market conditions.

Manufacturing within the U.S. offers numerous benefits that can significantly impact a company’s operational efficiency and market competitiveness. One of the primary advantages is enhanced quality control. By situating production facilities domestically, companies can closely monitor manufacturing processes, ensuring that products meet stringent quality standards. This proximity facilitates immediate oversight and swift response to any issues that may arise during production, thereby maintaining high-quality outputs.

Another notable benefit is the reduction in lead times. Domestic manufacturing eliminates the lengthy shipping durations associated with overseas production. This reduction not only accelerates the time-to-market for products but also enables companies to respond more rapidly to market demands and consumer needs. Shorter lead times can lead to increased customer satisfaction and a more agile supply chain.

Furthermore, manufacturing in the U.S. can result in decreased costs, including tariff and delivery charges. Producing goods closer to the consumer reduces transportation expenses, which can be a significant portion of a product’s overall cost. Lower delivery costs can enhance a company’s profitability and offer competitive pricing advantages in the marketplace.

Massimo Group’s recent announcement highlights the company’s proactive approach in leveraging these benefits. In response to U.S. trade regulators imposing countervailing duties and antidumping tariffs on certain foreign manufacturers accused of unfair trade practices, Massimo has decided to shift the production of its MVR Golf Cart series to its existing facility in Garland, Texas. This decision is aimed at enhancing quality control and strengthening the company’s presence in the U.S. market.

“We are committed to providing our customers with the highest quality golf carts while ensuring long-term business sustainability,” said David Shan, CEO of Massimo Motor. “Bringing production to our Texas facility strengthens our supply chain, enhances quality assurance and positions us competitively in the U.S. market. Our customers and dealer partners can continue to rely on Massimo for innovative and reliable personal transportation solutions.”

By relocating production domestically, Massimo is poised to mitigate the financial impact of international tariffs and duties. This move not only safeguards the company from potential cost increases associated with imported goods but also aligns with a broader trend of reshoring manufacturing operations to the United States. Reshoring can provide companies with greater control over their supply chains and reduce exposure to global trade uncertainties.

The Massimo Group has established itself as a significant entity in the powersports sector. The company’s product portfolio includes a range of off-road vehicles, such as all-terrain vehicles (“ATVs”), utility task vehicles (“UTVs”), and golf carts. By focusing on innovation and quality, Massimo has cultivated a reputation for delivering reliable and high-performance vehicles tailored to diverse consumer needs.

The company’s vision centers on providing exceptional products that enhance the recreational and professional experiences of its customers. By prioritizing quality and customer satisfaction, Massimo aims to be a leader in the powersports industry, continually adapting to market trends and consumer preferences.

For more information, visit the company’s website at massimomotor.com, massimomarine.com and massimoelectric.com

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO